One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database

Menzin, Joseph; Wygant, Gail; Hauch, Ole; Jackel, J; Friedman, Mark

doi:10.1185/030079908x261096

Cited by 99 publications

(66 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…-бюджетные потери в связи с реабилитацией и вре-менной/полной потерей трудоспособности; -расходы при повторном стентировании/КШ [14,28,32,40,49,54,60].…”

Section: кардиология и сердечно-сосудистая хирургия 2 2015unclassified

“…Бюджетные потери от повторных госпитализаций (20%) в 1-й год по-сле медикаментозной терапии, стентирования/КШ со-ставили 45,3, 41,2 и 43,5% соответственно [40,60]. Пер-вичная госпитализация больного с ОКС в США к 2009 г. обходилась в 71 336 долл.…”

Section: кардиология и сердечно-сосудистая хирургия 2 2015unclassified

See 1 more Smart Citation

Features of ischemic heart disease and myocardial revascularization in patients younger than 40 years

Abdullaev¹,

Mamedov²,

Багиров³

et al. 2015

Kardiol. serdechno-sosud. khir.

View full text Add to dashboard Cite

Section: кардиология и сердечно-сосудистая хирургия 2 2015unclassified

Features of ischemic heart disease and myocardial revascularization in patients younger than 40 years

Abdullaev¹,

Mamedov²,

Багиров³

et al. 2015

Kardiol. serdechno-sosud. khir.

View full text Add to dashboard Cite

“…[28][29][30][31][32][33][34][35][36][37][38][39] Utilities. The utilities for each health state were drawn from the literature and are also shown in Table 1.…”

Section: 22122mentioning

confidence: 99%

Effect of Including Cancer Mortality on the Cost-Effectiveness of Aspirin for Primary Prevention in Men

et al. 2013

View full text Add to dashboard Cite

BACKGROUND: Recent data suggest that aspirin may be effective for reducing cancer mortality. OBJECTIVE: To examine whether including a cancer mortality-reducing effect influences which men would benefit from aspirin for primary prevention. DESIGN: We modified our existing Markov model that examines the effects of aspirin among middle-aged men with no previous history of cardiovascular disease or diabetes. For our base case scenario of 45-year-old men, we examined costs and life-years for men taking aspirin for 10 years compared with men who were not taking aspirin over those 10 years; after 10 years, we equalized treatment and followed the cohort until death. We compared our results depending on whether or not we included a 22 % relative reduction in cancer mortality, based on a recent meta-analysis. We discounted costs and benefits at 3 % and employed a third party payer perspective. MAIN MEASURE: Cost per quality-adjusted life year (QALY) gained. KEY RESULTS: When no effect on cancer mortality was included, aspirin had a cost per QALY gained of $22,492 at 5 % 10-year coronary heart disease (CHD) risk; at 2.5 % risk or below, no treatment was favored. When we included a reduction in cancer mortality, aspirin became cost-effective for men at 2.5 % risk as well (cost per QALY, $43,342). Results were somewhat sensitive to utility of taking aspirin daily; risk of death after myocardial infarction; and effects of aspirin on stroke, myocardial infarction, and sudden death. However, aspirin remained cost-saving or cost-effective (< $50,000 per QALY) in probabilistic analyses (59 % with no cancer effect included; 96 % with cancer effect) for men at 5 % risk. CONCLUSIONS: Including an effect of aspirin on cancer mortality influences the threshold for prescribing aspirin for primary prevention in men. If such an effect is real, many middle-aged men at low cardiovascular risk would become candidates for regular aspirin use.

show abstract

“…6 More recently, Menzin and coworkers estimated the average cost (in 2005 dollars) of initial hospitalization for acute coronary syndromes to be $22,921, and their estimate for re-hospitalization for IHD was $28,637. 7 In other industrialized countries, the economic burden of IHD has also been very high. For example, in the United Kingdom (UK), Liu and associates estimated the total 1-year cost (1999) of IHD to be £7.06 billion, the highest of any disease in the UK.…”

Section: Introductionmentioning

confidence: 99%

“…To date, researchers have used a variety of approaches in investigating the health care costs of IHD. [4][5][6][7][8][9][10][11][12][13][14][15] For example, in the US, Hodgson and Cohen used a prevalence-based approach to demonstrate that IHD accounted for just over one half of health care expenditures for heart disease in 1995 ($38.7 billion of $75.9 billion.) 5 Russell et al, using a variety of data sources and a Markov model, estimated incidence-based first-year treatment costs of IHD in the US for that same year at $5.54 billion.…”

Section: Introductionmentioning

confidence: 99%

Inpatient Costs Associated with Ischemic Heart Disease Among Adults Aged 18-64 Years in the United States

Wang¹,

Zhang²,

Ayala³

et al. 2012

Novel Strategies in Ischemic Heart Disease

View full text Add to dashboard Cite

One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database

Cited by 99 publications

References 7 publications

Features of ischemic heart disease and myocardial revascularization in patients younger than 40 years

Features of ischemic heart disease and myocardial revascularization in patients younger than 40 years

Effect of Including Cancer Mortality on the Cost-Effectiveness of Aspirin for Primary Prevention in Men

Inpatient Costs Associated with Ischemic Heart Disease Among Adults Aged 18-64 Years in the United States

Contact Info

Product

Resources

About